Corcept Therapeutics (CORT) – Major News
-
Corcept Therapeutics (CORT) Tops Q4 EPS by 1c
-
Corcept Therapeutics (CORT) Tops Q3 EPS by 6c
-
Corcept Therapeutics (CORT) Tops Q2 EPS by 10c
-
Corcept Therapeutics (CORT) Misses Q1 EPS by 5c
-
Corcept Therapeutics (CORT) Misses Q4 EPS by 10c
-
Corcept Therapeutics (CORT) Tops Q2 EPS by 2c; Offers FY22 Revenue Guidance
-
Corcept Therapeutics (CORT) Tops Q3 EPS by 10c
-
Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
-
Corcept Therapeutics (CORT) Tops Q3 EPS by 4c, Revenues Miss; Narrows FY20 Revenue Guidance Below Consensus
-
Corcept Therapeutics (CORT) Tops Q2 EPS by 10c; Reaffirms
-
Corcept Therapeutics (CORT) Tops Q1 EPS by 12c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus
-
Corcept Therapeutics (CORT) Misses Q4 EPS by 1c
-
Corcept Therapeutics (CORT) Tops Q3 EPS by 11c
-
Corcept Therapeutics (CORT) Tops Q1 EPS by 1c
-
Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
-
Corcept Therapeutics (CORT) Tops Q3 EPS by 5c; Reaffirms
-
Corcept Therapeutics (CORT) Misses Q2 EPS by 4c; Lowers Outlook, $100M Stock Buyback
-
Corcept Therapeutics (CORT) Tops Q1 EPS by 3c
-
Corcept Therapeutics (CORT) Reports Q4 EPS of $0.77
-
Corcept Therapeutics (CORT) Misses Q3 EPS by 3c
-
Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook
-
Corcept Therapeutics (CORT) Misses Q1 EPS by 9c
-
Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
-
Corcept Therapeutics (CORT) Tops Q3 EPS by 3c
-
Corcept Therapeutics (CORT) Tops Q2 EPS by 2c
-
Corcept Therapeutics (CORT) Tops Q1 EPS by 1c
-
Corcept Therapeutics (CORT) Tops Q4 EPS by 3c; Issues Light FY16 Revenue Outlook
-
Corcept Therapeutics (CORT) Tops Q3 EPS by 1c
-
Corcept Therapeutics (CORT) Tops Q2 EPS by 2c
-
Corcept Therapeutics (CORT) Misses Q1 EPS by 1c
-
Corcept Therapeutics (CORT) Tops Q4 EPS by 4c
-
Corcept Therapeutics, Inc. (CORT) Misses Q1 EPS by 2c
-
Corcept Therapeutics, Inc. (CORT) Posts Q4 Loss of 11c/Share
-
Corcept Therapeutics, Inc. (CORT) Posts Q3 Loss of 8c/Share
-
Corcept Therapeutics, Inc. (CORT) Posts Q1 loss of 10c/Share
-
Corcept Therapeutics, Inc. (CORT) Reports In-Line Q4 Loss of 9c/Share
-
Corcept Therapeutics, Inc. (CORT) Tops Q3 EPS by 1c
-
Corcept (CORT) Sells Synthetic Capped Royalty on Future Sales for $30M; Terminates CEFF with Kingsbridge
-
Corcept Therapeutics, Inc. (CORT) Posts Narrower than Expected Q2 Loss of 9c/Share
-
Corcept Therapeutics, Inc. (CORT) Misses Q1 Loss views by 2c/Share
-
Corcept Therapeutics (CORT) Posts Wider than Expected Q4 loss of 12c/Share
-
Corcept Therapeutics, Inc. (CORT) Reports Q3 EPS Loss of $0.08
-
Corcept Therapeutics Inc. (CORT) Tops Q1 EPS by 1c
-
Corcept Therapeutics Inc. (CORT) Reports In-Line Q4 Loss
-
Corcept Therapeutics (CORT) Said CORLUX Phase 3 Study in Cushing's Syndrome Statistically Significant
-
Corcept Therapeutics (CORT) Posts In-Line Q3 Loss of $0.10
-
Corcept Therapeutics (CORT) Reports Q2 In-Line Loss of 9c
-
Corcept Therapeutics Inc. (CORT) Posts Q1 Loss of $0.10, Narrower Y/Y
-
Corcept Therapeutics Inc. (CORT) Posts Q4 Loss of $0.09, Narrower than Expectations
Back to CORT Stock Lookup